Marinus Pharmaceuticals Earlier Reported Q2 EPS $(0.24), Inline; Top-Line Phase 2 Refractory Status Epilepticus (Rse) Data On-Track For Q3 2019; Scott Braunstein Appointed As CEO; Nicole Vitullo Appointed As Chairman Of The Board